235 related articles for article (PubMed ID: 31792737)
61. Targeting cancer stem cells as therapeutic approach in the treatment of colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Hassanian SM; Parizadeh SMR; Vojdani S; Ghandehari M; Ghazaghi A; Khazaei M; Shahidsales S; Rezayi M; Asgharzadeh F; Ghayour-Mobarhan M; Ferns GA; Avan A
Int J Biochem Cell Biol; 2019 May; 110():75-83. PubMed ID: 30818083
[TBL] [Abstract][Full Text] [Related]
62. Third-line therapy for metastatic colorectal cancer.
Gundgaard MG; Soerensen JB; Ehrnrooth E
Cancer Chemother Pharmacol; 2008 Jan; 61(1):1-13. PubMed ID: 17786445
[TBL] [Abstract][Full Text] [Related]
63. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
Grapsa D; Syrigos K; Saif MW
Expert Rev Anticancer Ther; 2015; 15(11):1267-81. PubMed ID: 26506906
[TBL] [Abstract][Full Text] [Related]
64. Maintenance strategy in metastatic colorectal cancer: A systematic review.
Esin E; Yalcin S
Cancer Treat Rev; 2016 Jan; 42():82-90. PubMed ID: 26608114
[TBL] [Abstract][Full Text] [Related]
65. Melatonin modulates tumor metabolism and mitigates metastasis.
Reiter RJ; Sharma R; Tan DX; Huang G; de Almeida Chuffa LG; Anderson G
Expert Rev Endocrinol Metab; 2023; 18(4):321-336. PubMed ID: 37466337
[TBL] [Abstract][Full Text] [Related]
66. Perioperative melatonin use.
Jarratt J
Anaesth Intensive Care; 2011 Mar; 39(2):171-81. PubMed ID: 21485664
[TBL] [Abstract][Full Text] [Related]
67. Targeting IL-8 in colorectal cancer.
Ning Y; Lenz HJ
Expert Opin Ther Targets; 2012 May; 16(5):491-7. PubMed ID: 22494524
[TBL] [Abstract][Full Text] [Related]
68. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes.
Kanterman J; Sade-Feldman M; Biton M; Ish-Shalom E; Lasry A; Goldshtein A; Hubert A; Baniyash M
Cancer Res; 2014 Nov; 74(21):6022-35. PubMed ID: 25209187
[TBL] [Abstract][Full Text] [Related]
69. Letter to the editor: Panaxadiol's anticancer activity is enhanced by epicatechin.
Rodriguez M; Du GJ; Wang CZ; Yuan CS
Am J Chin Med; 2010; 38(6):1233-5. PubMed ID: 21061473
[TBL] [Abstract][Full Text] [Related]
70. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways.
Gao Y; Xiao X; Zhang C; Yu W; Guo W; Zhang Z; Li Z; Feng X; Hao J; Zhang K; Xiao B; Chen M; Huang W; Xiong S; Wu X; Deng W
J Pineal Res; 2017 Mar; 62(2):. PubMed ID: 27865009
[TBL] [Abstract][Full Text] [Related]
71. Is there a role for melatonin in supportive care?
Lissoni P
Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
[TBL] [Abstract][Full Text] [Related]
72. Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis.
Orendas P; Kubatka P; Kajo K; Stollarova N; Kassayova M; Bojkova B; Pec M; Nosal V; Kiskova T; Zihlavnikova K; Karsnakova R
Neoplasma; 2012; 59(4):469-74. PubMed ID: 22489703
[TBL] [Abstract][Full Text] [Related]
73. ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials.
Abdel-Rahman O
Int J Colorectal Dis; 2019 Dec; 34(12):2143-2150. PubMed ID: 31732876
[TBL] [Abstract][Full Text] [Related]
74. Therapeutic effects of melatonin on endometriosis, targeting molecular pathways: Current knowledge and future perspective.
Sharifi M; Rajabpoor Nikoo N; Badehnoosh B; Shafabakhsh R; Asemi R; Reiter RJ; Asemi Z
Pathol Res Pract; 2023 Mar; 243():154368. PubMed ID: 36774757
[TBL] [Abstract][Full Text] [Related]
75. Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis.
Kaveh S; Ebrahimi P; Rezapour A; Mozafari M; Sayehmiri K
Int J Clin Pharm; 2019 Feb; 41(1):30-41. PubMed ID: 30610548
[TBL] [Abstract][Full Text] [Related]
76. Antioxidant properties of melatonin and its potential action in diseases.
Karaaslan C; Suzen S
Curr Top Med Chem; 2015; 15(9):894-903. PubMed ID: 25697560
[TBL] [Abstract][Full Text] [Related]
77. A Review on Melatonin's Effects in Cancer: Potential Mechanisms.
Hanikoglu A; Kucuksayan E; Akduman RC; Ozben T
Anticancer Agents Med Chem; 2018; 18(7):985-992. PubMed ID: 29173185
[TBL] [Abstract][Full Text] [Related]
78. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
Cartwright TH
Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
[TBL] [Abstract][Full Text] [Related]
79. Melatonin and Cancer Hallmarks.
Talib WH
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495398
[TBL] [Abstract][Full Text] [Related]
80. The regulatory role of melatonin in skeletal muscle.
Chen B; You W; Shan T
J Muscle Res Cell Motil; 2020 Sep; 41(2-3):191-198. PubMed ID: 32157560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
